Newsletters

We now have the ability to play a key role in the evolution of CDISC standards. As a CDISC Gold member Algorithme Phama can further collaborate with global leaders and contribute toward the development and release of new standards.

Last October, Altasciences expanded into the United States with the opening of Algorithme Pharma USA, in Fargo, North Dakota. Today, we are pleased to announce that our first studies were initiated and completed in January, just 91 days from the US contract being signed, and despite the holiday hustle.

The Algorithme Pharma team provides full bioanalytical support for Large Molecules through all phases of clinical development, including as part of regulated studies.

Vince & Associates’ Stellar Regulatory History, Pharmacology Unit Expansion, Joins The Cardiac Safety Research Consortium, Qualified as Early Phase Provider for Clinical Evaluation of Thorough QT and Upcoming Presentations.

The impact of new partial AUC parameters for evaluating the bioequivalence of prolonged-release formulations, Thank you to everyone who joined us at the AAPS Annual Meeting in San Diego and Don't miss the 7th EBF Open Symposium!

Development and Validation of an ELISA for the Determination of AB-16B5 in Rat Serum, AAPS Annual Meeting, San Diego, Webinar — Impaired Renal Function Clinical Trials: Early Phase Planning to Minimize Risks and Accelerate Drug Development and 7th Open Symposium of EBF.

Biologics & Biosimilars: Key Considerations & Strategies in Early Stage Development and Overcoming the Bioanalysis Challenges of Biosimilars: Rituximab Case Study.